Yesterday, argenx's stock slipped by more than 2%—with its shares still down slightly as of Friday morning—after the Dutch ...
As a snarl of pharma-focused lawsuits from Texas Attorney General Ken Paxton play out, Gilead Sciences has worked out a deal ...
In this week's episode of "The Top Line," we're covering a pair of FDA approvals for GSK, an antibody-drug conjugate pact ...
The U.S. Treasury Department is closing in on American investments in China's life sciences industry as it issued draft rules ...
After disappointing Wall Street for most of 2026, Roche’s eye disease drug Vabysmo met analysts’ expectations for the first ...
Pfizer’s newest round of workforce cuts may be getting an early start. | Local news reported Pfizer layoffs in Michigan and ...
The FDA rebuked Baxter in a lengthy warning letter that outlined a series of production violations that led to a trio of ...
With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...
Esteve CDMO, the contract development and manufacturing organization within Spanish specialty pharma Esteve, is overhauling ...
In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...
The PMCPA has ruled that Otsuka Europe’s involvement with a sponsored symposium | The PMCPA has ruled that Otsuka Europe’s involvement with a sponsored symposium webpage breached 11 clauses of the U.K ...
Delaying the use of subcutaneous Parkinson’s disease treatments by one year increases annual medical costs by 59.1%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results